Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Operating Expenses (2016 - 2025)

Historic Operating Expenses for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $1.1 billion.

  • BeOne Medicines' Operating Expenses rose 1064.3% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 1241.9%. This contributed to the annual value of $3.8 billion for FY2024, which is 1514.5% up from last year.
  • Latest data reveals that BeOne Medicines reported Operating Expenses of $1.1 billion as of Q3 2025, which was up 1064.3% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Operating Expenses ranged from a high of $1.1 billion in Q2 2025 and a low of -$1.2 billion during Q4 2021
  • Its 5-year average for Operating Expenses is $722.3 million, with a median of $819.0 million in 2023.
  • In the last 5 years, BeOne Medicines' Operating Expenses tumbled by 29706.67% in 2021 and then soared by 14876.92% in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' Operating Expenses stood at -$1.2 billion in 2021, then surged by 148.77% to $562.2 million in 2022, then surged by 62.27% to $912.4 million in 2023, then rose by 14.72% to $1.0 billion in 2024, then grew by 0.57% to $1.1 billion in 2025.
  • Its Operating Expenses stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $941.2 million for Q1 2025.